Literature DB >> 23249229

Do we know the Th1/Th2/Th17 determinants of vaccine response?

Srinivas Garlapati1.   

Abstract

EVALUATION OF: Kamath AT, Mastelic B, Christensen D et al. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses. J. Immunol. 188(10), 4828–4837 (2012).The determinants of Th1/Th2/Th17 responses elicited by vaccine formulations are largely undefined and are an intense area of research. Most of the present licensed alum-adjuvanted subunit vaccines fail to elicit Th1/Th17 immune responses, and Th2 antibody responses are weak and often require repeated immunizations. Moreover, such responses are not sufficient for eliminating intracellular pathogens. Th1 responses have been traditionally elicited by live-attenuated, vector-based or Toll-like receptor ligand-adjuvanted formulations for optimal stimulation of the innate immune system and immunomodulation. The linkage of adjuvant and antigen (Ag) physically, and/or in a formulation, is essential to overcome systemic effects of the adjuvant and elicit Th1/Th17 responses. The role of delivery systems for codelivery of adjuvant and Ag to the same dendritic cell has gained acceptance. The milieu in which dendritic cells process and present Ag to naive CD4+ T cells determines their polarization into different subsets.

Entities:  

Year:  2012        PMID: 23249229     DOI: 10.1586/erv.12.111

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  5 in total

1.  Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.

Authors:  Sonali Kochhar
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

2.  Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant.

Authors:  Anna U Bielinska; Paul E Makidon; Katarzyna W Janczak; Luz P Blanco; Benjamin Swanson; Douglas M Smith; Tiffany Pham; Zsuzsanna Szabo; Jolanta F Kukowska-Latallo; James R Baker
Journal:  J Immunol       Date:  2014-02-14       Impact factor: 5.422

Review 3.  Heat Shock Proteins 90 kDa: Immunomodulators and Adjuvants in Vaccine Design Against Infectious Diseases.

Authors:  Mariana G Corigliano; Valeria A Sander; Edwin F Sánchez López; Víctor A Ramos Duarte; Luisa F Mendoza Morales; Sergio O Angel; Marina Clemente
Journal:  Front Bioeng Biotechnol       Date:  2021-01-20

Review 4.  Vaccine Adjuvants: from 1920 to 2015 and Beyond.

Authors:  Alberta Di Pasquale; Scott Preiss; Fernanda Tavares Da Silva; Nathalie Garçon
Journal:  Vaccines (Basel)       Date:  2015-04-16

5.  Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein.

Authors:  Heather L Torrey; Valarmathy Kaliaperumal; Yogesh Bramhecha; Genevieve M Weir; Ann R Falsey; Edward E Walsh; Joanne M Langley; Bert Schepens; Xavier Saelens; Marianne M Stanford
Journal:  Hum Vaccin Immunother       Date:  2020-06-12       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.